MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Effect of dopamine and L-3,4 – dihydroxyphenylalanine in treatment of experimental parkinsonism

    M.U. Kulmanova (Tashkent, Uzbekistan)

    Objective: To study effect of dopamine and L-3,4 - dihydroxyphenylalanine in treatment of experimental parkinsonism. Background: Prospects of treatment of Parkinson's disease are also closely…
  • 2016 International Congress

    Improving the experience of diagnosis in Parkinson’s disease

    C. Carroll, B. Blight, V. Evans, N. Hawkes, J. Davis (Plymouth, United Kingdom)

    Objective: To identify areas in which patient experience of being diagnosed with Parkinson's can be improved. Background: Receiving a Parkinson's diagnosis can leave patients feeling…
  • 2016 International Congress

    Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson’s disease

    L. Zhang, M. Wang, J. Zhu, Y. Pan, J. Dong (Nanjing, People's Republic of China)

    Objective: To Evaluate:prepared a MPTP/p induced mouse subacute model of PD, and explore the modulatory effect of H2S on monoamine and amino acid neurotransmitters in…
  • 2016 International Congress

    Inhibition of cathepsin D enhances the autophagy lysosome pathway dysfunction and α-synuclein aggregation in experimental parkinsonism

    L. Li, Y.P. Yang, L. Gao, Y. Song, Z. Liang (Suzhou, People's Republic of China)

    Objective: To explore the mechanism of CTSD inhibition in the dysfunction of autophagy-lysosome pathway and aggregation of α-synuclein in Parkinson's disease. Background: α-synuclein, the main…
  • 2016 International Congress

    Effect of repeated intravenous amantadine infusions in patients with Parkinson’s disease

    A. Khlebtovsky, I. Steiner, R. Djaldetti, T. Treves (Petach Tikva, Israel)

    Objective: To examine the long-term effect of repeated boosts of intravenous amantadine in patients with PD with and without response fluctuations and dyskinesias. Background: Amantadine…
  • 2016 International Congress

    Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease

    C. Mahapatra, R. Manchanda (Mumbai, India)

    Objective: Understanding the drug effects with respect to various ion channels on subthalamic nucleus (STN) cells is the key to safety pharmacology assessment. Here our…
  • 2016 International Congress

    A double blind investigation of efficacy and safety of incobotulinumtoxinA in Parkinson’s disease tremor- A customized injection approach

    S.O. Mittal, R. Rostami, D.G. Machado, D. Richardson, B. Jabbari (Cleveland, OH, USA)

    Objective: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection in the tremor of Parkinson's disease (PD). Background: Unlike other cardinal motor features of…
  • 2016 International Congress

    Serum level of vitamin D3 in patients with neurodegenerative diseases compared to healthy adults and its correlation with the years spent from the initial diagnosis

    A.N. Taravari (Skopje, Macedonia)

    Objective: Vitamin D is an important factor responsible for many physiologic functions. Vitamin D deficiency is associated with increased risk of neurodegenerative disease. Background: The…
  • 2016 International Congress

    Group climate in the voice therapy of patients with Parkinson’s disease

    G.L.A. Diaféria, P.B. Takaki, G. Madazio, C. Pacheco, M.S. Behlau (São Paulo, Brazil)

    Objective: To examine the impact of coaching and group dynamics activities in the voice, speech and communication of Parkinson's disease (PD) patients, as well as…
  • 2016 International Congress

    Activities of daily living and motor scores of the UPDRS in fluctuating Parkinson’s disease patients treated with opicapone

    J. Ferreira, A. Lees, O. Rascol, T. Müller, A. Santos, I. Oliveira, N. Lopes, J.F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: Evaluate the effects of opicapone (OPC) on the activities of daily living and motor scores of the UPDRS in fluctuating Parkinson's disease patients. Background:…
  • « Previous Page
  • 1
  • …
  • 204
  • 205
  • 206
  • 207
  • Next Page »
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley